Trial Profile

Observational study of safety and effectiveness of NovoMix 30 (biphasic insulin aspart) for the treatment of diabetes mellitus.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin aspart/insulin protamine aspart (Primary)
Indications Type 2 diabetes mellitus
Focus Adverse reactions
Acronyms IMPROVE
Sponsors Novo Nordisk

Most Recent Events

15 Jun 2012 Actual initiation date changed from 1 Feb 2006 to 1 Sep 2006 as reported by ClinicalTrials.gov.
14 Jan 2009 Actual patient number reported as 58223 by ClinicalTrials.gov.
14 Jan 2009 Actual end date reported as November 2008 by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com